Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b CX-2051 combination study with bevacizumab in earlier lines of CRC therapy.

Next Previous
Trial Profile

A Phase 1b CX-2051 combination study with bevacizumab in earlier lines of CRC therapy.

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 May 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Varsetatug masetecan (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions

Most Recent Events

  • 07 May 2026 According to the CytomX Therapeutics media release, Varseta-M doses to be assessed in combination with bevacizumab will include Q2W and Q4W schedules to align with the approved bevacizumab CRC dose of 5 mg/kg Q2W. Initial clinical data are anticipated by 1H 2027.
  • 16 Mar 2026 Status changed from planning to recruiting.
  • 08 Jan 2026 According to the CytomX Therapeutics media release, initial data is expected by first half of 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top